Physician profile
John Hennessey
NPI 1871559070
$6,955.65
in general payments reported to CMS, 2019-2025
47 companies · $43.76 in 2025
The $43.76 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,781 · 2020: $923 · 2021: $1,430 · 2022: $1,259 · 2023: $496 · 2024: $22.90 · 2025: $43.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,241.17 | 2019-2023 | |
| Biogen, INC. | $765.23 | 2019-2023 | Plegridy, Avonex, Vumerity |
| Abbvie INC. | $585.76 | 2019-2023 | |
| Genzyme Corporation | $448.36 | 2019-2022 | |
| Ucb, INC. | $428.49 | 2019-2023 | Briviact |
| Amgen INC. | $352.81 | 2019-2022 | |
| Emd Serono, INC. | $309.09 | 2019-2023 | Mavenclad |
| Allergan, INC. | $288.99 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $271.13 | 2019-2023 | Ultomiris |
| Genentech USA, INC. | $216.97 | 2019-2023 | Ocrevus |
| Supernus Pharmaceuticals, INC. | $192.58 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $173.49 | 2019 | |
| Amneal Pharmaceuticals LLC | $123.38 | 2020-2022 | |
| Mdd US Operations, LLC | $103.44 | 2020-2024 | Gocovri, Gocovri |
| Kyowa Kirin, INC. | $101.74 | 2020-2023 | Nourianz |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hennessey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.